Grade 3–5 Adverse effects | Gefitinib group (event/total) | Erlotinib group (event/total) | RR (95% CI) | P value | Heterogeneity | |
---|---|---|---|---|---|---|
I2 (%) | P value | |||||
Skin rash | 72/999 | 163/745 | 0.22 (0.12–0.41) | < 0.00001 | 73 | 0.0006 |
Diarrhea | 31/892 | 38/710 | 0.46 (0.29–0.74) | 0.001 | 0 | 0.46 |
Nausea/Vomiting | 8/639 | 27/531 | 0.23 (0.11–0.49) | 0.0001 | 20 | 0.29 |
Fatigue | 18/639 | 40/531 | 0.28 (0.09–0.87) | 0.03 | 74 | 0.02 |
Anorexia | 3/403 | 4/310 | 0.25 (0.06–1.04) | 0.06 | NA | NA |
Interstitial lung disease | 7/619 | 3/514 | 1.05 (0.27–4.06) | 0.95 | 17 | 0.3 |
Stomatitis | 3/260 | 8/169 | 0.28 (0.08–0.99) | 0.05 | 24 | 0.27 |
Elevated liver enzymes | 80/652 | 23/400 | 1.50 (0.97–2.31) | 0.07 | 0 | 0.64 |
Infection | 9/454 | 7/380 | 1.12 (0.46–2.69) | 0.8 | 20 | 0.28 |
Neutropenia | 2/399 | 3/379 | 0.67 (0.11–3.97) | 0.66 | NA | NA |